Report of Foreign Issuer (6-k)
September 12 2016 - 04:43PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 12 September 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
GlaxoSmithKline plc (the '
Company
’')
Transaction notification
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Sir Andrew Witty
|
b)
|
Position/status
|
CEO
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
The transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr S Dingemans
|
b)
|
Position/status
|
CFO
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr N Hirons
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
7 (partnership shares)
|
£16.1550
|
7 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
14 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr S A Hussain
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
7 (partnership shares)
|
£16.1550
|
7 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
14 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
SVP, Human Resources
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
7 (partnership shares)
|
£16.1550
|
7 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
14 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr P C Thomson
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
7 (partnership shares)
|
£16.1550
|
7 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
14 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mrs V A Whyte
|
b)
|
Position/status
|
Company Secretary
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of Ordinary Shares under the Company's
ShareReward Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.1550
|
8 (partnership shares)
|
£16.1550
|
8 (matching shares)
|
d)
|
Aggregated information
Aggregated volume Price
|
16 Ordinary shares
£16.1550
|
e)
|
Date of
the
transaction
|
2016-09-09
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: September 12, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024